Provention Bio - PRVB Stock Forecast, Price & News

Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.

Provention Bio Trading Up 6.4 %

PRVB Stock opened at $5.62 on Friday. Provention Bio has a twelve month low of $3.18 and a twelve month high of $8.04. The company has a market capitalization of $359.90 million, a P/E ratio of -3.41 and a beta of 2.45. The firm has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $5.20.

Provention Bio (NASDAQ:PRVB - Get Rating) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.46) EPS for the quarter, topping analysts' consensus estimates of ($0.49) by $0.03. The firm had revenue of $0.75 million during the quarter, compared to the consensus estimate of $0.80 million. Provention Bio had a negative net margin of 3,840.68% and a negative return on equity of 100.07%. During the same quarter in the previous year, the company posted ($0.46) earnings per share. On average, research analysts predict that Provention Bio will post -1.83 EPS for the current year.

Analyst Ratings Changes

Several analysts have issued reports on PRVB shares. Chardan Capital lowered their price objective on shares of Provention Bio from $22.50 to $21.00 and set a "buy" rating for the company in a research report on Friday, August 5th. HC Wainwright lowered their price objective on shares of Provention Bio from $25.00 to $18.00 and set a "buy" rating for the company in a research report on Monday, July 11th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $18.33.